Casirivimab is one of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies proposed for use in the clinical management of coronavirus disease 2019 (COVID-19). When used in combination with imdevimab, it reduces viral load and improves clinical outcomes. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of casirivimab therapy in the clinical setting and also highlights the essential points needed by members of an interprofessional team managing COVID-19 patients.